Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids

The aim of this study was to assess the bone mineral density (BMD) of premenopausal patients with systemic lupus erythematosus (SLE) on corticosteroids (CS) and to determine the influence of CS and other risk factors on BMD. A total of 98 premenopausal patients with SLE were recruited from outpatien...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2009-02, Vol.18 (2), p.178-181
Main Authors: Yeap, SS, Fauzi, AR, Kong, NCT, Halim, AG, Soehardy, Z, Rahimah, S, Chow, SK, Goh, EML
Format: Article
Language:English
Subjects:
Adolescent
Adrenal Cortex Hormones - adverse effects
Adult
Age
Bone Density
Cohort Studies
Drug dosages
Exercise
Female
Humans
Lupus
Lupus Erythematosus, Systemic - drug therapy
Malaysia
Middle Aged
Osteoporosis
Osteoporosis - chemically induced
Outpatient care facilities
Patients
Physical fitness
Premenopause
Risk factors
Smoking
Statistical analysis
Steroids
Teaching hospitals
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to assess the bone mineral density (BMD) of premenopausal patients with systemic lupus erythematosus (SLE) on corticosteroids (CS) and to determine the influence of CS and other risk factors on BMD. A total of 98 premenopausal patients with SLE were recruited from outpatient clinics in two teaching hospitals. Risk factors for osteoporosis were determined, and BMD was measured using dual-energy x-ray absorptiometry. The mean age of the patients was 30.05 ± 7.54 years. The mean dose of prednisolone at time of BMD measurement was 18.38 ± 10.85 mg daily. Median duration of CS use was 2.5 years (range 0–20). Median cumulative dose of CS was 9.04 g (range 0.28–890.0). Six patients (6.1%) had osteoporosis, 41 (41.9%) had osteopenia and 51 (52.0%) had normal BMD. Lumbar spine T score correlated with cumulative CS dose (P = 0.019). Duration of CS intake correlated with femoral neck T score (P = 0.04) and trochanter T score (P = 0.008). There was no correlation between BMD and race, SLE Disease Activity Index score, smoking and self-reported calcium intake or exercise. Only 52% of these patients had normal BMD. The duration and cumulative dose of CS intake was significantly correlated to BMD, but not the other commonly assessed risk factors. These findings suggest that premenopausal patients with SLE on CS should have their BMD measured at regular intervals to fully assess their osteoporosis risk.
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203308094995